The medtech business in 2025 stands on the slicing fringe of innovation, driving exceptional developments in diagnostics, distant care, AI-assisted surgical procedure and wearable well being applied sciences. But, regardless of its simple progress, the sector faces quite a lot of vital challenges that threaten to sluggish its momentum.
From complicated regulatory landscapes and escalating cybersecurity threats to rising R&D prices and the ever-present strain to reveal real-world affect, medtech firms are navigating a minefield of points. That’s, provide chain disruptions, expertise shortages and information privateness considerations are additional complicating issues, particularly for startups making an attempt to scale.
As healthcare turns into extra digital, linked and globalised, the stakes have by no means been increased. We’ve chatted to consultants within the business as a way to discover probably the most urgent hurdles confronting the medtech world in 2025, and what they imply for innovation, affected person outcomes and business development within the years to come back.
Navigating Regulation and Innovation: A Delicate Balancing Act
One of the vital urgent points for medtech firms in 2025 is the problem of balancing fast innovation with stringent regulatory compliance. As applied sciences evolve – notably these involving AI, machine studying and personalised medication – present regulatory frameworks usually wrestle to maintain up.
For startups and smaller companies, navigating these complicated, generally ambiguous, necessities may be each time-consuming and expensive. Delays in approvals can stall product launches and discourage funding, whereas differing worldwide requirements add additional layers of issue for firms aiming to scale globally.
On the identical time, regulators face strain to safeguard public security with out stifling innovation. This ongoing rigidity requires clearer steerage, stronger collaboration between regulators and innovators and extra adaptive frameworks that may evolve alongside the expertise itself. For medtech to thrive, regulation should turn out to be an enabler of innovation – not only a gatekeeper.
So, what do the consultants need to say? Let’s discover out.
Our Consultants:
- Lucy Hope: Founding father of The Daughters of Mars
- Fiona Garin: VP Strategic Advertising and Innovation EMEA, BD (Becton Dickinson)
- Laura Bowler: Senior Supervisor, Sustainability Consulting at Ramboll
- Andrew Archibald: CEO of Medmin
- Dr. Stuart Grant: Founder and Principal Guide of Archetype
- Mel Corridor: Authorized Director at Morton Fraser MacRoberts (MFMac)
- Timo Lehne: CEO of SThree
- Ian Burgess: Managing Director at Canary Care
- Collin Neale: Principal Mobile & LEO IoT Connectivity Specialist at Wi-fi Logic
- Joao Pereira: Director, EMEA, Normal Embedded Markets at QNX
- Tamaisha Eytle: Director of FutureBARBADOS
- Jeremy Gurewitz: Co-Founding father of Solace Well being
Lucy Hope, Founding father of The Daughters of Mars
‘
“Medtech can’t declare to be modern whereas girls’s well being stays many years behind. Circumstances like endometriosis, power UTIs and vaginal infections have an effect on hundreds of thousands but funding, analysis and medical innovation are shockingly scarce. Why? As a result of girls’s well being has been systematically deprioritised, dismissed as ‘too complicated’, ‘too hormonal’, or not commercially interesting.
This isn’t a scientific problem – it’s a structural and political one. Startups working on this area face investor bias, outdated laws and an absence of entry to gender-specific information. We want public funding and regulatory reform explicitly targeted on closing the gender well being hole. If policymakers are severe about innovation, they have to cease treating girls’s well being as a facet venture. The way forward for medtech is dependent upon it.”
Fiona Garin, VP Strategic Advertising and Innovation EMEA, BD (Becton Dickinson)
“Throughout EMEA, healthcare techniques face sustained strain: ageing populations, rising power illness, process backlogs, employees shortages, and cybersecurity threats are straining entry and resilience. On this context, medtech should not be considered as a ‘nice-to-have’, it’s important infrastructure.
The NHS Lengthy Time period Plan requires smarter, sooner, extra sustainable care. To ship it, we should embed medtech on the coronary heart of healthcare supply, not as pilots or one-off purchases, however as a strategic enabler of system-wide transformation.
At BD, we imagine the main focus have to be on what’s vital: tackling inefficiencies, supporting overstretched workforces, and driving safer, extra linked care. For instance, pharmacists spend over half their time on non-clinical duties – think about the affect of returning that point to affected person care.
However medtech can’t act alone. We want cross-sector collaboration, modernised procurement, and longer-term considering. Resilient healthcare calls for that we cease treating innovation as optionally available—and begin embracing it as important.
Laura Bowler, Senior Supervisor, Sustainability Consulting at Ramboll
“Sustainability will probably be one of many largest challenges within the medtech business within the coming years. Regardless of current shifts in laws and political administrations, total international strain to scale back carbon emissions and waste continues to develop. Medtech firms face the distinctive problem of making an attempt to steadiness environmental duty with the necessity for sterility, security, and innovation.
The business depends closely on single-use plastics, energy-intensive manufacturing, and complicated international provide chains, all of which may make decarbonization and circularity notably troublesome. On the identical time, growing regulatory scrutiny, investor expectations, and healthcare system calls for for sustainable merchandise are pushing the business to evolve.”
Andrew Archibald, CEO of Medmin
“The most important problem for MedTech? Proving it really works.
Healthcare is a high-stakes, high-scrutiny surroundings. It’s not sufficient to create tech that appears shiny or feels modern – you’ll want to present, unequivocally, that it makes a significant distinction to affected person outcomes.
The usual for MedTech is identical as for prescribed drugs: rigorous medical validation. Meaning managed trials, long-term information, and a weight of proof – not simply intelligent advertising or glossy design. Medication has a excessive bar for proof and a low tolerance for danger, for good purpose. Each new expertise have to be extra than simply protected and efficient within the brief time period; it wants to enhance well being outcomes considerably and sustainably.
As well being techniques face rising prices and growing scrutiny, “good to have” is just not adequate. The way forward for MedTech belongs to those that can rise up and say: Right here’s the proof. This makes folks higher.”
Dr. Stuart Grant, Founder and Principal Guide of Archetype
“MedTech R&D faces strain from a number of sides. Expertise shortages are delaying innovation – particularly the necessity for hybrid consultants who can bridge the hole between medical science and AI, software program, and person expertise.
With out these consultants, cross-functional improvement slows down. On the identical time, the prices and time wanted to carry a tool to market stay excessive. Lengthy improvement cycles, medical trials, and unsure reimbursement make buyers hesitant, which slows early-stage innovation. With extra gadgets linked to networks, cybersecurity turns into essential. R&D can’t overlook the significance of secure-by-design techniques, particularly when dealing with delicate well being information. Each weak spot can result in a regulatory, authorized, or reputational disaster.
Including to the problem is the growing demand for real-world proof. Regulators and payers now anticipate proof that gadgets work not solely in trials but additionally in on a regular basis medical settings. This requires constructing information assortment, monitoring, and analytics into the method from the outset, including further work for R&D groups and additional extending the event timeline, which necessitates further funding.”
Dr. Stuart Grant is considered one of our skilled judges taking part on this 12 months’s MedTech38 competitors.
Mel Corridor, Authorized Director at Morton Fraser MacRoberts (MFMac)
“One of many largest authorized challenges dealing with the medtech business is the shortage of worldwide regulatory alignment – notably with the UK now taking appearing steps to diverge from the EU strategy. Most medtech firms wish to commercialise their merchandise globally, however every jurisdiction comes with its personal regulatory framework. In observe, meaning navigating complicated, and generally divergent, necessities to entry key markets.
This problem turns into much more pronounced when firms develop AI-driven medical applied sciences. Whereas innovation on this area is accelerating, regulatory certainty is lagging. The EU AI Act and the UK’s pro-innovation AI framework differ – making it complicated for firms to scale confidently throughout borders.
To beat this, medtech companies want tailor-made authorized methods that think about cross-jurisdictional compliance, information governance, and long-term product lifecycle planning. With out this, they danger pricey delays in bringing life-changing applied sciences to sufferers.”
Timo Lehne, CEO of SThree
“Medtech is without doubt one of the fastest-moving innovation sectors however sustaining that momentum is dependent upon a dependable pipeline of specialist STEM expertise, and proper now, that’s one of many business’s largest vulnerabilities.
From biomedical engineers to information scientists, demand is rising quick, but the expertise pipeline isn’t conserving tempo. Whereas educational foundations are robust, we’re not changing data into functionality at scale. Too usually, expert graduates lack clear pathways into business, and companies are hiring for roles that didn’t exist 5 years in the past.
However the problem goes deeper. Regulatory complexity, post-Brexit uncertainty, and tightening funding circumstances are all placing strain on development. On the identical time, inside expertise, the engine of long-term innovation, is being stretched skinny.
If we would like medtech to thrive, we want pressing motion on workforce technique: higher coordination between academia and employers, smarter funding in rising expertise, and stronger incentives to draw and retain specialist expertise. The way forward for medtech is dependent upon it.”
Ian Burgess, Managing Director at Canary Care
“The MedTech business faces quite a lot of challenges within the coming years. Though the federal government has dedicated to integrating expertise into the well being and care sectors, innovation and digital transformation have to be matched by actual, sensible motion. At the moment, too many native authorities and NHS groups are nonetheless struggling to entry and implement the expertise that makes a distinction.
Moreover, the safety of a person’s information will pose an enormous problem to the MedTech business. Making certain that confidential information stays safe must be paramount for medical expertise suppliers to make sure affected person security, and to take care of affected person belief.
Lastly, medical expertise should stay straightforward to make use of, to keep away from implications of expertise expertise gaps for customers, households and healthcare employees. To make sure medical expertise is seamlessly built-in into present techniques, a mix of intuitive expertise and enough coaching have to be obtainable.”
If you need additional particulars or want to organize an interview, please let me know. Ian can be glad to offer further commentary on the challenges and downfalls of Tech Enabled Care adoption in social care, or to debate a possible byline on this matter in case you are .
Joao Pereira, Director, EMEA, Normal Embedded Markets at QNX
“The NHS’s ambition to considerably broaden robot-assisted surgical procedures presents a transparent path to tackling persistently lengthy ready lists, pushed by the confirmed effectivity and accuracy these applied sciences present. Latest QNX analysis reveals a robust urge for food for the rollout of robotics inside healthcare and wider business, with virtually two-thirds (64%) of UK organisations eager to undertake them.
Regardless of positivity for the position robotics can play, a regarding hole exists between this ambition and tangible motion as solely 12% of UK expertise business leaders have concrete plans to implement robotics within the subsequent 12 months, and practically a 3rd (29%) stay undecided. This hesitation is rooted in uncertainty and security considerations, with 43% of leaders in healthcare organisations itemizing ‘security’ as a big issue influencing their belief in robotics.
The NHS should prioritise trusted, high-performance, real-time options that adhere to rigorous security requirements and supply complete, foundational security measures. Choosing the proper expertise will enable us to revolutionize the sphere of robot-assisted surgical procedures, setting new requirements for the way forward for healthcare, making certain that robotics really ship on ambitions to enhance affected person outcomes and cut back ready occasions.”
Tamaisha Eytle, Director of FutureBARBADOS
“Medtech innovation is a world problem—however its affect is felt most acutely in small island nations like Barbados, the place rising healthcare prices, fragmented techniques, and low tech adoption stretch already restricted assets.
Fixing this isn’t nearly introducing new instruments. It requires a citizen-centred, multisectoral shift—and the intentional constructing of an innovation ecosystem that helps creation, not simply consumption.
FutureHEALTH is designed to drive that transformation. By connecting coverage reform, data change, and innovation help throughout public, personal, educational, and diaspora networks, it goals to unlock real-world options that enhance care, cut back prices, and construct long-term system resilience.”
Jeremy Gurewitz, Co-Founding father of Solace Well being
“In my position because the founding father of a company that works to enhance healthcare within the U.S. and provides everybody a voice of their healthcare, the medical expertise business faces vital challenges which will affect its future. Regulatory hurdles, such because the F.D.A.’s altering oversight of AI, may require costly compliance, slowing improvements like A.I.-powered diagnostics, which could possibly catch ailments earlier. For instance, the FDA’s 2024 steerage on predetermined change management plans for AI, which goals to steadiness between innovation and security, however slows market entry for startups. Cybersecurity is equally pressing; ransomware incidents towards healthcare grew 40% from 2020 to 2023, endangering affected person data and system operation (like within the 2023 IBM insulin pump flaw).
Provide chain instability, pushed by 50% tariffs on metal and aluminum, means the price of gadgets like stents is pushed up, whereas reimbursement points restrict affected person entry to cutting-edge gadgets. My group pushes for clear pricing and diversified sourcing to stabilize prices. Solely by breaking down these boundaries can we be assured we’re offering a degree enjoying discipline for medtech to carry life-saving improvements to sufferers – and that is, after all, our mission.”
